This site is intended for U.S. healthcare professionals.
Menu
Close
Close
In the single-arm, Phase 2 MagnetisMM-3 study, 57.7% ORR (56/97) and 51.5% ≥VGPR (50/97) were achieved in adult RRMM who had no prior BCMA-directed therapy and had received at least four prior lines of therapy. Among all responding patients, the DoR rate at 9 months was 82.3%.2
ELREXFIO is an off-the-shelf BCMA-directed bispecific immunotherapy2
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.